Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Reiser

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Cancer|December 7, 2005
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaNobert Schmitz, Marita Kloess, Marcel Reiser, et al.
Journal of Cancer Research and Clinical Oncology|June 11, 2022
Awareness and use of psychosocial care among cancer patients and their relatives-a comparison of people with and without a migration background in GermanySusanne Singer, Nicola Riccetti, Isabelle Hempler, et al.
Blood|January 2, 2003
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupUte Rehwald, Holger Schulz, Marcel Reiser, et al.
Annals of Hematology|July 1, 2008
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)Carsten Zwick, Josef Birkmann, Norma Peter, et al.
BMC Cancer|February 26, 2020
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center studyC Benedikt Westphalen, Tobias Kukiolka, Benjamin Garlipp, et al.
International Journal of Cancer|July 3, 2024
Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort studyNorbert Marschner, Nina Haug, Susanna Hegewisch-Becker, et al.
European Journal of Haematology|February 3, 2018
Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practiceMarcel Reiser, Steffen Dörfel, Manfred Hensel, et al.
Blood|December 4, 2013
Suboptimal dosing of rituximab in male and female patients with DLBCLMichael Pfreundschuh, Carsten Müller, Samira Zeynalova, et al.
Blood|March 16, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Annals of Hematology|March 13, 2024
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practicesGeorg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Cancer|December 7, 2005
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaNobert Schmitz, Marita Kloess, Marcel Reiser, et al.
Journal of Cancer Research and Clinical Oncology|June 11, 2022
Awareness and use of psychosocial care among cancer patients and their relatives-a comparison of people with and without a migration background in GermanySusanne Singer, Nicola Riccetti, Isabelle Hempler, et al.
Blood|January 2, 2003
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupUte Rehwald, Holger Schulz, Marcel Reiser, et al.
Annals of Hematology|July 1, 2008
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)Carsten Zwick, Josef Birkmann, Norma Peter, et al.
BMC Cancer|February 26, 2020
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center studyC Benedikt Westphalen, Tobias Kukiolka, Benjamin Garlipp, et al.
International Journal of Cancer|July 3, 2024
Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort studyNorbert Marschner, Nina Haug, Susanna Hegewisch-Becker, et al.
European Journal of Haematology|February 3, 2018
Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practiceMarcel Reiser, Steffen Dörfel, Manfred Hensel, et al.
Blood|December 4, 2013
Suboptimal dosing of rituximab in male and female patients with DLBCLMichael Pfreundschuh, Carsten Müller, Samira Zeynalova, et al.
Blood|March 16, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Annals of Hematology|March 13, 2024
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practicesGeorg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, et al.
Pageof 8